NASDAQ:XGN Exagen (XGN) Stock Price, News & Analysis $3.76 -0.01 (-0.27%) Closing price 04:00 PM EasternExtended Trading$3.76 +0.01 (+0.13%) As of 04:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Exagen Stock (NASDAQ:XGN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Exagen alerts:Sign Up Key Stats Today's Range$3.64▼$3.9150-Day Range$3.77▼$8.7452-Week Range$2.59▼$9.22Volume1.33 million shsAverage Volume426,081 shsMarket Capitalization$95.92 millionP/E RatioN/ADividend YieldN/APrice Target$9.88Consensus RatingModerate Buy Company Overview Exagen Inc. is a diagnostics company focused on testing for autoimmune and rheumatic diseases. It develops and provides blood tests intended to help physicians assess and monitor conditions such as systemic lupus erythematosus and other connective tissue diseases. The company’s AVISE test portfolio includes diagnostic and monitoring tests that use proprietary biomarkers to support clinical evaluation. Its offerings are designed to provide information that may help clinicians distinguish among autoimmune conditions and guide patient care. Exagen is based in Vista, California, and serves healthcare providers and patients in the United States. Its business centers on laboratory testing and related diagnostic services for autoimmune disease.AI Generated. May Contain Errors. Read More Exagen Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks81st Percentile Overall ScoreXGN MarketRank™: 4.060140415945 of 5 starsExagen scored higher than 81% of companies evaluated by MarketBeat, and ranked 81st out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingExagen has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 1 strong buy rating, 7 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialExagen has a consensus price target of $9.88, representing about 165.4% upside from its current price of $3.72.Amount of Analyst CoverageExagen has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Exagen's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Exagen are expected to grow in the coming year, from ($0.71) to ($0.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Exagen is -4.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Exagen is -4.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioExagen has a P/B Ratio of 6.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.35% of the float of Exagen has been sold short.Short Interest Ratio / Days to CoverExagen has a short interest ratio ("days to cover") of 1.98, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Exagen has recently increased by 7.96%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldExagen does not currently pay a dividend.Dividend GrowthExagen does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment0.40 News SentimentExagen has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 36 news articles for Exagen this week, compared to 3 articles on an average week.Search Interest9 people have searched for XGN on MarketBeat in the last 30 days. MarketBeat Follows4 people have added Exagen to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Exagen insiders have sold 90.77% more of their company's stock than they have bought. Specifically, they have bought $568,660.00 in company stock and sold $1,084,856.00 in company stock.Percentage Held by Insiders10.40% of the stock of Exagen is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions75.25% of the stock of Exagen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Exagen's insider trading history. Receive XGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exagen and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. XGN Stock News HeadlinesExagen (NASDAQ:XGN) Major Shareholder Sells $236,917.44 in StockNovember 15 at 2:22 PM | insidertrades.comExagen (NASDAQ:XGN) Major Shareholder Acquires $372,977.45 in StockNovember 15 at 1:10 PM | americanbankingnews.comDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall. The free download walks through strategies for navigating the options market, but the window to claim it is closing soon.November 17 at 1:00 AM | TradeWins (Ad)Exagen Earnings Call Highlights Growth and Platform ExpansionNovember 15 at 2:18 AM | tipranks.comExagen (NASDAQ:XGN) Stock Gets Price Target Trim from Canaccord Genuity GroupNovember 14 at 2:31 AM | americanbankingnews.comExagen (NASDAQ:XGN) Major Shareholder Jorey Chernett Purchases 71,315 Shares of StockNovember 13, 2026 | insidertrades.comExagen (NASDAQ:XGN) Stock: Insider Jorey Chernett Buys 7,085 SharesNovember 11, 2026 | insidertrades.comExagen (NASDAQ:XGN) Major Shareholder Acquires $104,440.00 in StockOctober 21, 2026 | insidertrades.comSee More Headlines XGN Stock Analysis - Frequently Asked Questions How have XGN shares performed this year? Exagen's stock was trading at $6.08 at the start of the year. Since then, XGN stock has decreased by 38.8% and is now trading at $3.7210. How were Exagen's earnings last quarter? Exagen Inc. (NASDAQ:XGN) issued its quarterly earnings data on Tuesday, November, 10th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by $0.07. The company had revenue of $18.42 million for the quarter, compared to analyst estimates of $18.34 million. Exagen had a negative net margin of 25.14% and a negative trailing twelve-month return on equity of 125.60%. Read the conference call transcript. When did Exagen IPO? Exagen (XGN) raised $54 million in an initial public offering (IPO) on Thursday, September 19th 2019. The company issued 3,600,000 shares at $14.00-$16.00 per share. Cowen, Cantor and William Blair acted as the underwriters for the IPO. Who are Exagen's major shareholders? Top institutional investors of Exagen include Mink Brook Asset Management LLC (2.08%), First Eagle Investment Management LLC (2.13%), Marshall Wace LLP (1.54%) and Flputnam Investment Management Co. (1.18%). Insiders that own company stock include Nmsic Co-Investment Fund, LP, John Aballi, John Aballi and Kamal Adawi. View institutional ownership trends. How do I buy shares of Exagen? Shares of XGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Exagen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Exagen investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), Alibaba Group (BABA), Snap (SNAP), Advanced Micro Devices (AMD), Amneal Pharmaceuticals (AMRX) and Accuray (ARAY). Company Calendar Last Earnings11/10/2026Today11/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 7 days, XGN's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Providers & Services Sub-IndustryHealthcare Services Current SymbolNASDAQ:XGN CIK1274737 Webwww.exagen.com Phone760-560-1501FaxN/AEmployees220Year Founded2002Price Target and Rating Average Price Target for Exagen$9.88 High Price Target$12.00 Low Price Target$8.00 Potential Upside/Downside+162.6%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($0.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$19.95 million Net Margins-25.14% Pretax Margin-25.07% Return on Equity-125.60% Return on Assets-33.46% Debt Debt-to-Equity Ratio1.73 Current Ratio3.46 Quick Ratio3.18 Sales & Book Value Annual Sales$66.57 million Price / Sales1.44 Cash FlowN/A Price / Cash FlowN/A Book Value$0.54 per share Price / Book6.96Miscellaneous Outstanding Shares25,510,000Free Float22,860,000Market Cap$95.92 million OptionableOptionable Beta2.25 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:XGN) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exagen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exagen With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.